Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90001 DDI Study
NCT03363815Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CC-90001 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration up to 2.5 months and Area Under the Curve from time zero to last measurable concentration up to 2.5 months. Started Dec 2017; status: completed.
02
Drugs
CC-90001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03363815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363815.